Horizon Therapeutics PLC (HZNP): Price and Financial Metrics
HZNP Price/Volume Stats
Current price | $116.30 | 52-week high | $116.38 |
Prev. close | $116.25 | 52-week low | $60.03 |
Day low | $116.26 | Volume | 28,881,200 |
Day high | $116.38 | Avg. volume | 2,498,525 |
50-day MA | $109.80 | Dividend yield | N/A |
200-day MA | $108.24 | Market Cap | 26.63B |
HZNP Stock Price Chart Interactive Chart >
Horizon Therapeutics PLC (HZNP) Company Bio
Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (Source:Wikipedia)
Latest HZNP News From Around the Web
Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
Rule 17(e) Announcement - Horizon Therapeutics plcDUBLIN, October 06, 2023-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION |
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)DUBLIN, October 03, 2023--IRISH TAKEOVER PANEL |
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023DUBLIN, October 02, 2023--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2023. |
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient OutcomesDUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023. |
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care IndustryDUBLIN, September 26, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing. |
HZNP Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | 0.53% |
1-year | 6.81% |
3-year | 45.05% |
5-year | 340.03% |
YTD | N/A |
2023 | 0.00% |
2022 | 5.61% |
2021 | 47.31% |
2020 | 102.07% |
2019 | 85.26% |
Continue Researching HZNP
Want to do more research on Horizon Therapeutics Public Ltd Co's stock and its price? Try the links below:Horizon Therapeutics Public Ltd Co (HZNP) Stock Price | Nasdaq
Horizon Therapeutics Public Ltd Co (HZNP) Stock Quote, History and News - Yahoo Finance
Horizon Therapeutics Public Ltd Co (HZNP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...